Letter by Cardinale et al Regarding Article, “Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial”-Reference-Cited by-同舟云学术

Letter by Cardinale et al Regarding Article, “Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial”

Published:2024-05-28 Issue:22 Volume:149 Page:
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Cardinale Daniela¹^ORCID,Lyon Alexander R.²^ORCID,López-Fernández Teresa³⁴^ORCID

Affiliation:

1. Cardioncology Unit, European Institute of Oncology, IRCCS, Milan, Italy (D.C.).

2. Cardio-Oncology Service, Royal Brompton & Harefield NHS Foundation Trust and the National Heart & Lung Institute, Imperial College London, UK (A.R.L.).

3. Cardiology Department, La Paz University Hospital, IdiPAZ Research Institute, Madrid, Spain (T.L.-F.).

4. Cardiology Department, Quiron Pozuelo University Hospital, Madrid, Spain (T.L.-F.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference5 articles.

1. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial

2. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

3. Test–retest reliability of left and right ventricular systolic function by new and conventional echocardiographic and cardiac magnetic resonance parameters

4. Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy

5. Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition